S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
OTCMKTS:GTBP

GT Biopharma (GTBP) Stock Forecast, Price & News

$2.67
+0.01 (+0.38%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.51
$2.70
50-Day Range
$1.64
$3.04
52-Week Range
$1.51
$19.73
Volume
140,456 shs
Average Volume
170,862 shs
Market Capitalization
$81.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.59
30 days | 90 days | 365 days | Advanced Chart
Receive GTBP News and Ratings via Email

Sign-up to receive the latest news and ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter.

GT Biopharma logo

About GT Biopharma

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

Headlines

GT Biopharma names Manu Ohri as CFO
GT Biopharma Appoints Manu Ohri as Chief Financial Officer
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:GTBP
Previous Symbol
OTCMKTS:OXISD
Fax
N/A
Employees
8
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.58 per share

Profitability

Net Income
$-58.01 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
27,707,000
Market Cap
$81.44 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/16/2022
Today
5/21/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.55 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













GT Biopharma (OTCMKTS:GTBP) Frequently Asked Questions

Is GT Biopharma a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GT Biopharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GT Biopharma stock.
View analyst ratings for GT Biopharma
or view top-rated stocks.

When is GT Biopharma's next earnings date?

GT Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for GT Biopharma
.

How were GT Biopharma's earnings last quarter?

GT Biopharma, Inc. (OTCMKTS:GTBP) released its quarterly earnings results on Monday, May, 16th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.14.
View GT Biopharma's earnings history
.

What price target have analysts set for GTBP?

2 brokerages have issued twelve-month target prices for GT Biopharma's stock. Their forecasts range from $18.00 to $24.00. On average, they expect GT Biopharma's stock price to reach $21.00 in the next year. This suggests a possible upside of 686.5% from the stock's current price.
View analysts' price targets for GT Biopharma
or view top-rated stocks among Wall Street analysts.

Who are GT Biopharma's key executives?
GT Biopharma's management team includes the following people:
  • Mr. Michael Martin Breen, Interim CEO & Exec. Chairman (Age 59, Pay $378.02k)
  • Dr. Gregory I. Berk M.D., Pres of R&D, Chief Medical Officer and Member of Scientific Advisor Board (Age 64, Pay $526.39k)
  • Dr. Gavin S. Choy MBA, PharmD, Chief Clinical Devel. Officer
  • Mr. Manu Ohri, Chief Financial Officer (Age 67)
  • Dr. Jeffrey S. Miller M.D., Consulting Chief Scientific Officer & Scientific Advisor
  • Ms. Stacy Herb M.B.A., M.P.H., Sr. VP of Portfolio Management
What other stocks do shareholders of GT Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GT Biopharma investors own include Cronos Group (CRON), (CGC), Canopy Growth (WEED), Auxly Cannabis Group (CBWTF), KushCo (KSHB), Aurora Cannabis (ACBFF), Alibaba Group (BABA), Cara Therapeutics (CARA), American Cannabis (AMMJ) and GW Pharmaceuticals (GWPH).

What is GT Biopharma's stock symbol?

GT Biopharma trades on the OTCMKTS under the ticker symbol "GTBP."

Who are GT Biopharma's major shareholders?

GT Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.48%), Vanguard Group Inc. (2.99%), State Street Corp (1.46%), Renaissance Technologies LLC (0.56%), Northern Trust Corp (0.50%) and Charles Schwab Investment Management Inc. (0.12%).
View institutional ownership trends for GT Biopharma
.

Which major investors are selling GT Biopharma stock?

GTBP stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Renaissance Technologies LLC, Goldman Sachs Group Inc., State Street Corp, BlackRock Inc., Charles Schwab Investment Management Inc., Northern Trust Corp, and Simplex Trading LLC.
View insider buying and selling activity for GT Biopharma
or view top insider-selling stocks.

Which major investors are buying GT Biopharma stock?

GTBP stock was bought by a variety of institutional investors in the last quarter, including Allspring Global Investments Holdings LLC, Sigma Planning Corp, Russell Investments Group Ltd., and Atria Wealth Solutions Inc..
View insider buying and selling activity for GT Biopharma
or or view top insider-buying stocks.

How do I buy shares of GT Biopharma?

Shares of GTBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GT Biopharma's stock price today?

One share of GTBP stock can currently be purchased for approximately $2.67.

How much money does GT Biopharma make?

GT Biopharma has a market capitalization of $81.44 million. The company earns $-58.01 million in net income (profit) each year or ($1.01) on an earnings per share basis.

How many employees does GT Biopharma have?

GT Biopharma employs 8 workers across the globe.

What is GT Biopharma's official website?

The official website for GT Biopharma is www.gtbiopharma.com.

How can I contact GT Biopharma?

GT Biopharma's mailing address is 9350 Wilshire Blvd. Suite 203, Beverly Hills CA, 90212. The company can be reached via phone at (800) 304-9888 or via email at [email protected].

This page was last updated on 5/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.